Compositions of and methods of treatment with zwitterionic polysaccharide
AssigneesCity of Hope, California Institute of Technology
InventorsEdouard Cantin, Sarkis K. Mazmanian, Chandran Ramakrishna
Life of this patent
Estimating the term…
Abstract
The present disclosure includes compositions of a zwitterionic polysaccharide (e.g., B. fragilis capsular polysaccharide A (PSA)) (including active fragments thereof) and methods of treating viral infection and viral infection associated inflammation with compositions of a zwitterionic polysaccharide (e.g., B. fragilis capsular polysaccharide A (PSA)) (including active fragments thereof).
Claims12
A method of treating a viral infection in a subject in need thereof, the method comprising administering to said subject an effective amount of a zwitterionic polysaccharide, wherein (i) the effective amount is effective to reduce neuroinflammation in the subject, and (ii) the zwitterionic polysaccharide is a zwitterionic bacterial polysaccharide or a zwitterionic capsular polysaccharide.
A method of modulating an immune response in a subject in need thereof, the method comprising administering to said subject an effective amount of a zwitterionic polysaccharide and an effective amount of an anti-viral agent, wherein:
- (a) the effective amount of the zwitterionic polysaccharide is effective to reduce neuroinflammation in the subject;
- (b) the zwitterionic polysaccharide is a zwitterionic bacterial polysaccharide or a zwitterionic capsular polysaccharide;
- and
- (c) said subject has a viral infection selected from the group consisting of:
- varicellazoster virus infection, cytomegalovirus infection, Epstein-Barr virus infection, herpesvirus infection, West-Nile virus infection, polyomavirus infection, adenovirus infection, respiratory syncytial virus infection, norovirus infection, and influenza virus infection.
Dependencies are inferred from the claim text.